Previous Close | 1.8500 |
Open | 1.8500 |
Bid | 0.0000 |
Ask | 2.6500 |
Strike | 4.00 |
Expire Date | 2025-01-17 |
Day's Range | 1.8500 - 1.8500 |
Contract Range | N/A |
Volume | |
Open Interest | 10 |
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise Rita Karachun Rita Karachun - Coherus Director REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Kar
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Salary of US$982.9k is part of CEO...